Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate

NCT00095147 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT00095147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00095147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2005
Completion date
July 31, 2009
Enrollment
431 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis